Want to see OFIX full AI Analyst Report?
OFIX Stock Chart & Stats
$12.01
-$0.08(-0.47%)
At close: 4:00 PM EST
$12.01
-$0.08(-0.47%)
Day’s Range― - ―
52-Week Range$8.85 - $16.99
Previous CloseN/A
Volume45.16K
Average Volume (3M)212.06K
Market Cap
$377.94M
Enterprise Value$487.20M
Total Cash (Recent Filing)$120.28M
Total Debt (Recent Filing)$234.39M
Price to Earnings (P/E)―
Beta1.03
Next Earnings
Aug 11, 2026EPS Estimate
-0.41Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.51
Shares Outstanding40,421,654
10 Day Avg. Volume220,565
30 Day Avg. Volume212,061
Financial Highlights & Ratios
PEG Ratio0.22
Price to Book (P/B)1.34
Price to Sales (P/S)0.74
P/FCF Ratio-472.73
Enterprise Value/Market Cap1.29
Enterprise Value/Revenue0.59
Enterprise Value/Gross Profit0.86
Enterprise Value/Ebitda5.16
Forecast
1Y Price Target
$15.00Price Target Upside24.90% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)-1.16
Revenue Forecast (FY)$840.89M
Bulls Say, Bears Say
Bulls Say
Revenue Growth And ScaleOrthofix's sizeable $825M TTM revenue and recent acceleration provide durable scale to support commercial investment, R&D and fixed-cost leverage. Sustained mid-single-digit growth can underpin product rollouts and distributor engagement, improving operating leverage over multiple quarters.
High Gross MarginsA ~71% gross margin is a structural advantage in medical devices, giving flexibility to fund innovation and absorb pricing/reimbursement shocks. Continued margin expansion in guidance suggests durable improvements in mix, cost discipline and pricing that support sustainable profitability if execution persists.
Commercial Execution & PipelineStrong top-distributor growth and completed distributor transitions signal improved field execution and concentration with high-performing partners. Combined with multiple planned launches (VIRATA, TrueLok Elevate, Fitbone), this supports durable revenue upside from adoption and cross-sell over the next 2-6 months and beyond.
Bears Say
Reimbursement RiskA structural ~10% Medicare reimbursement cut for non-invasive bone growth stimulators materially reduces margin and cash conversion in a core product line. Because public payor rules persist, this recalibrates long-term revenue and profitability assumptions and raises uncertainty around sustainable pricing and utilization.
Negative ProfitabilityDespite revenue and margin gains, the company remains loss-making on a TTM basis. Persisting negative net and EBIT margins indicate that scale hasn't fully translated to sustainable earnings, leaving the business reliant on continued margin improvement and disciplined SG&A to reach consistent profitability.
Weak Free Cash Flow & ContingenciesSlightly negative TTM free cash flow and use of debt tranches to bolster liquidity signal limited internal cash generation. Potential legal settlements and withdrawn targets increase downside to cash flow, constraining reinvestment and forcing greater dependence on financing until positive, repeatable FCF is established.
Orthofix Medical News
OFIX FAQ
What was Orthofix Medical’s price range in the past 12 months?
Orthofix Medical lowest stock price was $8.85 and its highest was $16.99 in the past 12 months.
What is Orthofix Medical’s market cap?
Orthofix Medical’s market cap is $377.94M.
When is Orthofix Medical’s upcoming earnings report date?
Orthofix Medical’s upcoming earnings report date is Aug 11, 2026 which is in 39 days.
How were Orthofix Medical’s earnings last quarter?
Orthofix Medical released its earnings results on May 05, 2026. The company reported -$0.52 earnings per share for the quarter, beating the consensus estimate of -$0.68 by $0.16.
Is Orthofix Medical overvalued?
According to Wall Street analysts Orthofix Medical’s price is currently Undervalued.
Does Orthofix Medical pay dividends?
Orthofix Medical does not currently pay dividends.
What is Orthofix Medical’s EPS estimate?
Orthofix Medical’s EPS estimate is -0.41.
How many shares outstanding does Orthofix Medical have?
Orthofix Medical has 40,421,654 shares outstanding.
What happened to Orthofix Medical’s price movement after its last earnings report?
Orthofix Medical reported an EPS of -$0.52 in its last earnings report, beating expectations of -$0.68. Following the earnings report the stock price went up 3.58%.
Which hedge fund is a major shareholder of Orthofix Medical?
Currently, no hedge funds are holding shares in OFIX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Orthofix Medical Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$15.00 (24.90% Upside)
$15.00 (24.90% Upside)
Blogger Sentiment
Neutral
OFIX Sentiment 50%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 30.0K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $2.2M over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-11.13%
12-Months-Change
Fundamentals
Return on Equity
-13.44%
Trailing 12-Months
Asset Growth
7.71%
Trailing 12-Months
Company Description
Orthofix Medical
Orthofix Medical Inc., founded in 1980 and headquartered in Lewisville, Texas, operates as a global medical technology company focusing on devices and biologics. Its reach extends across the United States, several European nations including Italy, Germany, France, and the United Kingdom, as well as Brazil and other international markets. The company's operations are divided into two main segments: Global Spine and Global Orthopedics. Within the Global Spine division, Orthofix is responsible for the development, production, and distribution of bone growth stimulators. These devices are designed to facilitate bone fusion and serve as a therapeutic intervention for fractures located outside the spine and in the limbs. This segment also creates and commercializes a range of motion preservation and fixation implant products utilized in spinal surgical procedures. Furthermore, it supplies physicians with various tissue forms and synthetic-based regenerative biologic solutions to address a wide spectrum of spinal and orthopedic conditions. The Global Orthopedics segment concentrates on the design, development, and commercialization of specialized orthopedic products. These offerings are essential for procedures involving fracture repair, the correction of deformities, and bone reconstruction. Orthofix distributes its products to a diverse clientele, including physicians, hospitals, outpatient surgery centers, and integrated health delivery systems. This is achieved through a comprehensive sales network that includes its own sales force, independent distributors, and both employed and external sales representatives. The company, previously known as Orthofix International N.V., officially changed its name to Orthofix Medical Inc. in July 2018.
OFIX Company Deck
OFIX Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call conveyed steady, disciplined execution with several clear operational and commercial positives: modest top-line growth in Q1, strong performance among top distributors, outperformance in Therapeutic Solutions, improving gross margin, a healthy innovation pipeline (7D, TrueLok Elevate, Fitbone, VIRATA) and reaffirmed full-year guidance. At the same time, challenges persist—Biologics remains soft, U.S. Limb Reconstruction growth was flat, absolute EBITDA was modest, and some results were influenced by timing, mix and prior commercial transitions. Management emphasized that distributor transitions are largely behind them and discussed focused leadership changes and product launches to drive acceleration through the year. Overall, the positives and negatives are balanced, with evidence of improving momentum but meaningful operational work still required.View all OFIX earnings summariesOFIX Stock 12 Month Forecast
All Analysts
Top Analysts
Average Price Target
$15.00
▲(24.90% Upside)
Technical Analysis
1 Day
3 Days
1 Week
1 Month
Ownership Overview
14.58% Insiders
12.35% Mutual Funds
51.99% Other Institutional Investors
8.85% Public Companies and
Individual Investors






